MA-HOLOGIC-INC
Hologic, Inc. (Nasdaq: HOLX) announced today that the ThinPrep® Genesis processor for cytology slide and molecular test preparation has received a CE IVD mark in Europe. The system features increased automation capabilities, together with ergonomic and chain of custody benefits, compared to older instruments. Most importantly, the instrument will prepare slides for cytology as well as aliquot samples for molecular testing, reducing manual sample handling.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190418005130/en/
The Genesis processor is the latest extension of the ThinPrep portfolio, which revolutionized and increased the accuracy of cervical cancer screening with the first liquid-based Pap test in 1996. Hologic launched an updated ThinPrep® 2000 processor in 2017 and received FDA approval in 2018 for the ThinPrep® Integrated Imager, which guides cytotechnologists to areas showing potential abnormal cells. Studies have shown that automated, assisted imaging can increase the sensitivity of detecting suspicious cells compared to manual slide review.1-4
“The launch of the ThinPrep Genesis processor reflects our ongoing commitment to helping our lab customers deliver accurate and reliable results to clinicians and patients, while maximizing their operational efficiency,” said Jan Verstreken, Hologic’s Regional President, EMEA and Canada. “Over the last 30 years, mortality from cervical cancer has fallen significantly in the developed world, largely due to screening programs that identify abnormalities before they become cervical cancer.”
The ThinPrep Genesis processor provides the same trusted reliability as the ThinPrep 2000 system for cytology slide processing, with added features such as automated aliquoting for molecular testing. The processor also provides automated barcoding of samples, ensuring accurate sample tracking as well as reducing manual steps. The increased automation is expected to deliver ergonomic benefits by reducing repetitive strain.
To learn more about ThinPrep Pap test products, please visit: https://healthdxs.com/en/thinprep/ .
About Cervical Cancer and Pap+HPV Together
Hologic is a leading supplier in Europe of Pap tests (ThinPrep) and HPV tests (Aptima®). These tests can be used on the same sample to screen for cervical pre-cancer and cancer (independently or together for co-testing: Pap+HPV together).
Data from 2018 indicate that in Europe, more than 60,000 women were diagnosed with cervical cancer and approximately 25,000 died from the disease.5 Before introduction of the Pap test, cervical cancer was the leading cause of cancer-related deaths for women in Europe, but now ranks 9th in frequency.5
About eight out of 10 women will contract HPV, the virus that causes cervical cancer, at some point in their lives, but most of the time the virus goes away. In some cases, however, it can remain and promote development of cervical cancer. For women between 30 and 65, the co-testing screening approach has been shown to detect 95 percent of cervical cancer cases.6 Screening with both tests also prevents more cases of pre-cancer than either test used alone.6 In fact, the largest retrospective study of cervical cancer testing strategies found that one out of five cases of cancer was missed when the HPV test was used alone.6
More information about the value of co-testing is available at PapPlusHPV.com .
About Hologic
Hologic, Inc. is an innovative medical technology company primarily focused on improving women’s health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com .
Forward-Looking Statements
This press release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic’s diagnostic products. There can be no assurance these products will achieve the benefits described herein or that such benefits will be replicated in any particular manner with respect to an individual patient. The actual effect of the use of the products can only be determined on a case-by-case basis depending on the particular circumstances and patient in question. In addition, there can be no assurance that these products will be commercially successful or achieve any expected level of sales. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such statements are based.
Hologic, ThinPrep, Aptima, and The Science of Sure are trademarks and/or registered trademarks of Hologic, Inc. in the United States and/or other countries.
References
- Dziura B, et al. Performance of an imaging system vs. manual screening in the detection of squamous intra epithelial lesions of the uterine cervix. Acta Cytol . 2006;50(3):309-11.
- Lozano R. Comparison of computer-assisted and manual screening of cervical cytology. Gynecol Oncol . 2007;104(1):134-8.
- Miller FS, et al. Implementation of the ThinPrep imaging system in a high-volume metropolitan laboratory. Diagn Cytopathol. 2007;35(4):213-7.4.
- Klug SJ, et al. A randomized trial comparing conventional cytology to liquid-based cytology and computer assistance. Int J Cancer. 2012;132(12):2849-57. doi:10.1002/ijc.27955.
- ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases Report, 17 April 2018. http://www.hpvcentre.net/statistics/reports/XEX.pdf 1
- Blatt et al. Comparison of cervical cancer screening results among 256,648 women in multiple clinical practices. Cancer Cytopathology . 2015;123(5):282-288 [Study included ThinPrep®, SurePath®, Hybrid Capture® 2 assay].
SOURCE: Hologic, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190418005130/en/
Contact:
Investor Contact: Michael Watts +1 858.410.8588 michael.watts@hologic.com
Media Contact: Jane Mazur +1 508.263.8764 (direct) +1 585.355.5978 (mobile) jane.mazur@hologic.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LambdaTest and SVAM International Inc. Announce Partnership to Transform Quality Engineering for Businesses26.11.2025 18:00:00 CET | Press release
The alliance empowers enterprises with accelerated SDLC cycles, reduced testing effort, and modern AI-driven digital transformation capabilities LambdaTest, a Gen-AI native quality engineering platform, announced a partnership with SVAM International, Inc., a global leader in digital transformation services. This strategic alliance marks a significant step forward in their mission to transform quality engineering for businesses worldwide. The partnership allows LambdaTest to extend its AI-native quality engineering capabilities into SVAM’s extensive digital transformation ecosystem. By integrating with SVAM’s experience in large-scale application development, testing, and delivery across major New York State and City agencies, as well as their platform expertise across Salesforce, ServiceNow, and Dynamics365, LambdaTest will empower more enterprises to modernize their software delivery pipelines. With LambdaTest’s intelligent test orchestration and execution engine at the core, teams c
GLORY Acquires Remaining Equity Shares in Acrelec Group26.11.2025 16:11:00 CET | Press release
Acrelec becomes a wholly owned subsidiary of Glory Glory Global Solutions (International) Ltd, a wholly-owned subsidiary of GLORY Ltd. [TYO:6457], has announced the acquisition of the remaining equity shares in Acrelec Group SAS. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251126039437/en/ Acrelec is a global technology company focused on reinventing the customer experience for restaurant and retail brands. Leveraging decades of software, hardware and service expertise, the company develops and integrates new platforms that increase customer engagement, optimize efficiency and improve operations. With over 120,000 installations across more than 70 countries, Acrelec counts many of the world’s best-known restaurant mega-brands among its customers. We announce that Jalel Souissi has left the Acrelec Group following the completion of the recent share acquisition. Jalel Souissi has played a pivotal role in the development and
Andersen Global styrker sin platform i Tyrkiet med tilføjelsen af medlemsvirksomhed26.11.2025 14:49:00 CET | Pressemeddelelse
Andersen Global udvider sin tilstedeværelse i Tyrkiet, efter at Celen Corporate Property Valuation & Counseling Inc. bliver til Andersen i Tyrkiet, hvilket udvider de kompetencer, der tilbydes under Andersen-brandet i landet. Det Istanbul-baserede firma blev stiftet i 1995 og ledes af Managing Partner Guniz Celen med en bred vifte af ydelser til både nationale og internationale kunder. Med ekspertise inden for finansiering af fast ejendom, værdiansættelse af materielle og immaterielle aktiver samt formueforvaltning leverer den tyrkiske afdeling af Andersen løsninger, der understøtter komplekse finansielle beslutninger for kunder i mere end 18 lande. “Vores mission har altid været at levere løsninger på de mest komplekse udfordringer inden for ejendoms- og investeringssektoren,” sagde Guniz. “At blive en del af Andersen-brandet styrker vores kompetencer som en betroet rådgiver og giver os adgang til globale ressourcer, hvilket gør os i stand til at skabe endnu større langsigtet værdi fo
Cegid Acquires Shine to Accelerate the Path of Becoming Europe's Leading Financial Copilot for SMBs and Accountants26.11.2025 14:00:00 CET | Press release
Transformative combination creates a powerhouse for SMBs and accountants, empowering businesses across Europe by integrating leading suites of e-invoicing, digital accounting, business accounts and payments, and HR solutions into a unified platform. Cegid, a European leader in cloud software for finance, accounting, HR, and retail software, and Shine, a fast-growing European fintech unicorn providing digital business accounts and payments, e-invoicing, accounting, and payroll software to small businesses across Europe, announced today that the companies have entered a definitive agreement to join forces to form a European champion and become a leading provider of software for businesses and their accountants. This transformational combination will create the first fully integrated, cloud-native and AI-driven financial hub for SMBs and accounting professionals in Europe – bringing together market-leading capabilities in e-invoicing, accounting, digital business accounts and payments, ta
U.S. FDA Grants Priority Review to Sonrotoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma26.11.2025 12:00:00 CET | Press release
If approved, sonrotoclax will become the first BCL2 inhibitor for R/R MCL in the U.S., addressing a high unmet need in an aggressive cancerSonrotoclax previously received Breakthrough Therapy Designation based on clinically meaningful, rapid responses in R/R MCLBeOne Medicines will present the data supporting the NDA and Priority Review for the first time at ASH 2025 BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to a New Drug Application (NDA) for sonrotoclax, a next-generation BCL2 inhibitor, for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL), following treatment with a Bruton’s tyrosine kinase (BTK) inhibitor. “Sonrotoclax is advancing with remarkable speed, from Breakthrough Therapy Designation to Priority Review, all within a short window,” said Lai Wang, Ph.D., Global Head of R&D at BeOne.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom